These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

538 related items for PubMed ID: 11160644

  • 1. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2.
    Riendeau D, Percival MD, Brideau C, Charleson S, Dubé D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):558-66. PubMed ID: 11160644
    [Abstract] [Full Text] [Related]

  • 2. Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.
    Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC.
    Br J Pharmacol; 1997 May; 121(1):105-17. PubMed ID: 9146894
    [Abstract] [Full Text] [Related]

  • 3. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Ford-Hutchinson AW, Forrest MJ, Gauthier JY, Gordon R, Gresser M, Guay J, Kargman S, Kennedy B, Leblanc Y, Leger S, Mancini J, O'Neill GP, Ouellet M, Patrick D, Percival MD, Perrier H, Prasit P, Rodger I.
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [Abstract] [Full Text] [Related]

  • 4. Valdecoxib: assessment of cyclooxygenase-2 potency and selectivity.
    Gierse JK, Zhang Y, Hood WF, Walker MC, Trigg JS, Maziasz TJ, Koboldt CM, Muhammad JL, Zweifel BS, Masferrer JL, Isakson PC, Seibert K.
    J Pharmacol Exp Ther; 2005 Mar; 312(3):1206-12. PubMed ID: 15494548
    [Abstract] [Full Text] [Related]

  • 5. Comparison of the cyclooxygenase-1 inhibitory properties of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, using sensitive microsomal and platelet assays.
    Riendeau D, Charleson S, Cromlish W, Mancini JA, Wong E, Guay J.
    Can J Physiol Pharmacol; 1997 Sep; 75(9):1088-95. PubMed ID: 9365818
    [Abstract] [Full Text] [Related]

  • 6. Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.
    Esser R, Berry C, Du Z, Dawson J, Fox A, Fujimoto RA, Haston W, Kimble EF, Koehler J, Peppard J, Quadros E, Quintavalla J, Toscano K, Urban L, van Duzer J, Zhang X, Zhou S, Marshall PJ.
    Br J Pharmacol; 2005 Feb; 144(4):538-50. PubMed ID: 15655513
    [Abstract] [Full Text] [Related]

  • 7. A high level of cyclooxygenase-2 inhibitor selectivity is associated with a reduced interference of platelet cyclooxygenase-1 inactivation by aspirin.
    Ouellet M, Riendeau D, Percival MD.
    Proc Natl Acad Sci U S A; 2001 Dec 04; 98(25):14583-8. PubMed ID: 11717412
    [Abstract] [Full Text] [Related]

  • 8. Pharmacological analysis of cyclooxygenase-1 in inflammation.
    Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, Talley JJ, Masferrer JL, Seibert K, Isakson PC.
    Proc Natl Acad Sci U S A; 1998 Oct 27; 95(22):13313-8. PubMed ID: 9789085
    [Abstract] [Full Text] [Related]

  • 9. Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: a novel compound exhibiting a marked preference for the human enzyme in intact cells.
    Berg J, Fellier H, Christoph T, Kremminger P, Hartmann M, Blaschke H, Rovensky F, Towart R, Stimmeder D.
    Naunyn Schmiedebergs Arch Pharmacol; 2000 Apr 27; 361(4):363-72. PubMed ID: 10763850
    [Abstract] [Full Text] [Related]

  • 10. In vitro metabolism considerations, including activity testing of metabolites, in the discovery and selection of the COX-2 inhibitor etoricoxib (MK-0663).
    Chauret N, Yergey JA, Brideau C, Friesen RW, Mancini J, Riendeau D, Silva J, Styhler A, Trimble LA, Nicoll-Griffith DA.
    Bioorg Med Chem Lett; 2001 Apr 23; 11(8):1059-62. PubMed ID: 11327589
    [Abstract] [Full Text] [Related]

  • 11. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers.
    Van Hecken A, Schwartz JI, Depré M, De Lepeleire I, Dallob A, Tanaka W, Wynants K, Buntinx A, Arnout J, Wong PH, Ebel DL, Gertz BJ, De Schepper PJ.
    J Clin Pharmacol; 2000 Oct 23; 40(10):1109-20. PubMed ID: 11028250
    [Abstract] [Full Text] [Related]

  • 12. Preclinical pharmacology profile of CS-706, a novel cyclooxygenase-2 selective inhibitor, with potent antinociceptive and anti-inflammatory effects.
    Ushiyama S, Yamada T, Murakami Y, Kumakura S, Inoue S, Suzuki K, Nakao A, Kawara A, Kimura T.
    Eur J Pharmacol; 2008 Jan 06; 578(1):76-86. PubMed ID: 17920584
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The anti-inflammatory effects of ZLJ-6, a novel dual cyclooxygenase/5-lipoxygenase inhibitor.
    Li L, Ji H, Sheng L, Zhang Y, Lai Y, Chen X.
    Eur J Pharmacol; 2009 Apr 01; 607(1-3):244-50. PubMed ID: 19243697
    [Abstract] [Full Text] [Related]

  • 15. Synthesis, structure-activity relationships, and in vivo evaluations of substituted di-tert-butylphenols as a novel class of potent, selective, and orally active cyclooxygenase-2 inhibitors. 2. 1,3,4- and 1,2,4-thiadiazole series.
    Song Y, Connor DT, Sercel AD, Sorenson RJ, Doubleday R, Unangst PC, Roth BD, Beylin VG, Gilbertsen RB, Chan K, Schrier DJ, Guglietta A, Bornemeier DA, Dyer RD.
    J Med Chem; 1999 Apr 08; 42(7):1161-9. PubMed ID: 10197960
    [Abstract] [Full Text] [Related]

  • 16. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
    Panara MR, Renda G, Sciulli MG, Santini G, Di Giamberardino M, Rotondo MT, Tacconelli S, Seta F, Patrono C, Patrignani P.
    J Pharmacol Exp Ther; 1999 Jul 08; 290(1):276-80. PubMed ID: 10381787
    [Abstract] [Full Text] [Related]

  • 17. Characterization of etoricoxib, a novel, selective COX-2 inhibitor.
    Dallob A, Hawkey CJ, Greenberg H, Wight N, De Schepper P, Waldman S, Wong P, DeTora L, Gertz B, Agrawal N, Wagner J, Gottesdiener K.
    J Clin Pharmacol; 2003 Jun 08; 43(6):573-85. PubMed ID: 12817520
    [Abstract] [Full Text] [Related]

  • 18. Pharmacological profile of FK881(ASP6537), a novel potent and selective cyclooxygenase-1 inhibitor.
    Imanishi J, Morita Y, Yoshimi E, Kuroda K, Masunaga T, Yamagami K, Kuno M, Hamachi E, Aoki S, Takahashi F, Nakamura K, Miyata S, Ohkubo Y, Mutoh S.
    Biochem Pharmacol; 2011 Oct 01; 82(7):746-54. PubMed ID: 21745460
    [Abstract] [Full Text] [Related]

  • 19. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.
    Famaey JP.
    Inflamm Res; 1997 Nov 01; 46(11):437-46. PubMed ID: 9427063
    [Abstract] [Full Text] [Related]

  • 20. The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity.
    Tacconelli S, Capone ML, Sciulli MG, Ricciotti E, Patrignani P.
    Curr Med Res Opin; 2002 Nov 01; 18(8):503-11. PubMed ID: 12564662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.